Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 320

1.

Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson's disease.

Olanow CW, Savolainen M, Chu Y, Halliday GM, Kordower JH.

Brain. 2019 Jun 1;142(6):1690-1700. doi: 10.1093/brain/awz104.

PMID:
31056668
2.

Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less.

Olanow CW.

Mov Disord. 2019 Jun;34(6):812-815. doi: 10.1002/mds.27690. Epub 2019 Apr 16. No abstract available.

PMID:
30990922
3.

Adverse event reporting in clinical trials in Parkinson's Disease: Time for change.

Olanow CW, Kenney C, Bandak S, Kieburtz KD.

Mov Disord. 2018 Nov;33(11):1685-1687. doi: 10.1002/mds.27497. Epub 2018 Nov 1. No abstract available.

PMID:
30383315
4.

Movement disorder society criteria for clinically established early Parkinson's disease.

Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schäffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB.

Mov Disord. 2018 Oct;33(10):1643-1646. doi: 10.1002/mds.27431. Epub 2018 Aug 25.

PMID:
30145841
5.

Huntington's disease: Current and future therapeutic prospects.

Kieburtz K, Reilmann R, Olanow CW.

Mov Disord. 2018 Jul;33(7):1033-1041. doi: 10.1002/mds.27363. Epub 2018 May 8. Review.

PMID:
29737569
6.

Do subjects with minimal motor features have prodromal Parkinson disease?

Chu Y, Buchman AS, Olanow CW, Kordower JH.

Ann Neurol. 2018 Mar;83(3):562-574. doi: 10.1002/ana.25179. Epub 2018 Mar 10.

7.

New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States.

Kieburtz K, Katz R, Olanow CW.

Mov Disord. 2018 Jul;33(6):920-927. doi: 10.1002/mds.27220. Epub 2017 Dec 4. No abstract available.

PMID:
29205505
8.

Levodopa: A new look at an old friend.

Olanow CW, Stocchi F.

Mov Disord. 2018 Jul;33(6):859-866. doi: 10.1002/mds.27216. Epub 2017 Nov 27. Review.

PMID:
29178365
9.

Translating scientific advances into disease-modifying therapies for Parkinson's Disease.

Cenci MA, Olanow CW.

Exp Neurol. 2017 Dec;298(Pt B):135-136. doi: 10.1016/j.expneurol.2017.10.011. No abstract available.

PMID:
29145992
10.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ.

Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review.

11.

Clinical approaches to the development of a neuroprotective therapy for PD.

Olanow CW, Kieburtz K, Katz R.

Exp Neurol. 2017 Dec;298(Pt B):246-251. doi: 10.1016/j.expneurol.2017.06.018. Epub 2017 Jun 13. Review.

PMID:
28622912
12.

A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.

Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, Klepiskaya OS, Kreitzman DL, Lew MF, Russell DS, Kadosh S, Litman P, Friedman H, Linvah N, The P B Study Group F.

Mov Disord. 2017 May;32(5):783-789. doi: 10.1002/mds.26941. Epub 2017 Apr 3.

PMID:
28370340
13.

Targeting α-Synuclein as a therapy for Parkinson's disease: The battle begins.

Olanow CW, Kordower JH.

Mov Disord. 2017 Feb;32(2):203-207. doi: 10.1002/mds.26935. No abstract available.

PMID:
28218461
14.

Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient.

Kordower JH, Goetz CG, Chu Y, Halliday GM, Nicholson DA, Musial TF, Marmion DJ, Stoessl AJ, Sossi V, Freeman TB, Olanow CW.

Ann Neurol. 2017 Jan;81(1):46-57. doi: 10.1002/ana.24820. Epub 2017 Jan 6.

15.

Abolishing the 1-year rule: How much evidence will be enough?

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G.

Mov Disord. 2016 Nov;31(11):1623-1627. doi: 10.1002/mds.26796. Epub 2016 Sep 26. No abstract available.

PMID:
27666574
16.

Long-term effects of rasagiline and the natural history of treated Parkinson's disease.

Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW; AFU Investigators.

Mov Disord. 2016 Oct;31(10):1489-1496. doi: 10.1002/mds.26724.

PMID:
27431201
17.

Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.

Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, Dubow J, Agro A.

Mov Disord. 2016 Sep;31(9):1366-72. doi: 10.1002/mds.26697. Epub 2016 Jul 19.

PMID:
27430123
18.

The new definition and diagnostic criteria of Parkinson's disease.

Postuma RB, Berg D, Adler CH, Bloem BR, Chan P, Deuschl G, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Oertel W, Olanow CW, Poewe W, Stern M.

Lancet Neurol. 2016 May;15(6):546-8. doi: 10.1016/S1474-4422(16)00116-2. Epub 2016 Apr 11. No abstract available.

PMID:
27302120
19.

Fetal grafts for Parkinson's disease: Decades in the making.

Kordower JH, Olanow CW.

Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):6332-4. doi: 10.1073/pnas.1606342113. Epub 2016 May 31. No abstract available.

20.

Trophic factors for Parkinson's disease: To live or let die.

Olanow CW, Bartus RT, Volpicelli-Daley LA, Kordower JH.

Mov Disord. 2015 Nov;30(13):1715-24. doi: 10.1002/mds.26426. Review.

PMID:
26769457
21.

Eldad Melamed 1942-2015: Ave atque--A memorial.

Olanow CW, Poewe W.

Mov Disord. 2016 Jan;31(1):39-40. doi: 10.1002/mds.26491. Epub 2015 Dec 18. No abstract available. Erratum in: Mov Disord. 2016 Mar;31(3):433.

PMID:
26685050
22.

MDS research criteria for prodromal Parkinson's disease.

Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G.

Mov Disord. 2015 Oct;30(12):1600-11. doi: 10.1002/mds.26431. Review.

PMID:
26474317
23.

MDS clinical diagnostic criteria for Parkinson's disease.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G.

Mov Disord. 2015 Oct;30(12):1591-601. doi: 10.1002/mds.26424. Review.

PMID:
26474316
24.

Advances in clinical trials for movement disorders.

Kieburtz K, Olanow CW.

Mov Disord. 2015 Sep 15;30(11):1580-7. doi: 10.1002/mds.26371. Epub 2015 Aug 26. Review.

PMID:
26307591
25.

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.

Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG.

Lancet Neurol. 2015 Aug;14(8):855-866. doi: 10.1016/S1474-4422(15)00006-X. Epub 2015 Jun 3. Review.

26.

Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies.

Bartus RT, Kordower JH, Johnson EM Jr, Brown L, Kruegel BR, Chu Y, Baumann TL, Lang AE, Olanow CW, Herzog CD.

Neurobiol Dis. 2015 Jun;78:162-71. doi: 10.1016/j.nbd.2015.03.023. Epub 2015 Apr 2.

PMID:
25841760
27.

Levodopa: effect on cell death and the natural history of Parkinson's disease.

Olanow CW.

Mov Disord. 2015 Jan;30(1):37-44. doi: 10.1002/mds.26119. Epub 2014 Dec 11. Review.

PMID:
25502620
28.

Profile of Mahlon DeLong and Alim Benabid, 2014 Lasker-DeBakey Medical Research awardees.

Olanow CW, Obeso J.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17693-5. doi: 10.1073/pnas.1419249111. Epub 2014 Dec 8. No abstract available.

29.

Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.

Lees AJ, Tolosa E, Olanow CW.

Mov Disord. 2015 Jan;30(1):19-36. doi: 10.1002/mds.26120. Epub 2014 Dec 8. Review.

PMID:
25488030
30.

The end of the term.

Olanow CW, Obeso JA.

Mov Disord. 2014 Dec;29(14):1703-4. doi: 10.1002/mds.26106. No abstract available.

PMID:
25487521
31.

Reply to: psychogenic movement disorders: what's in a name?

Fahn S, Olanow CW.

Mov Disord. 2014 Nov;29(13):1699-701. doi: 10.1002/mds.26042. Epub 2014 Oct 12. No abstract available.

PMID:
25308926
32.

Scientific perspectives.

Standaert DG, Olanow CW, Obeso JA.

Mov Disord. 2014 Sep;29(10):1230. doi: 10.1002/mds.26015. No abstract available.

PMID:
25209257
33.

Impact factor for 2013.

Olanow CW, Obeso JA.

Mov Disord. 2014 Aug;29(9):1091. doi: 10.1002/mds.26002. No abstract available.

PMID:
25137429
34.

Peripheral alpha-synuclein and Parkinson's disease.

Olanow CW, Wakeman DR, Kordower JH.

Mov Disord. 2014 Jul;29(8):963-6. doi: 10.1002/mds.25966. No abstract available.

PMID:
25043799
35.

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.

Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S.

Lancet Neurol. 2014 Aug;13(8):767-76. doi: 10.1016/S1474-4422(14)70148-6. Epub 2014 Jul 6.

PMID:
25008546
36.

Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives.

Schapira AH, Olanow CW, Greenamyre JT, Bezard E.

Lancet. 2014 Aug 9;384(9942):545-55. doi: 10.1016/S0140-6736(14)61010-2. Epub 2014 Jun 18. Review.

PMID:
24954676
37.

"Psychogenic movement disorders": they are what they are.

Fahn S, Olanow CW.

Mov Disord. 2014 Jun;29(7):853-6. doi: 10.1002/mds.25899. Epub 2014 May 5. No abstract available.

PMID:
24797587
38.

Parkinson disease: Gene therapy for Parkinson disease--a hope, or a dream?

Olanow CW.

Nat Rev Neurol. 2014 Apr;10(4):186-7. doi: 10.1038/nrneurol.2014.45. Epub 2014 Mar 25. No abstract available.

PMID:
24662536
39.

Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.

Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G.

Mov Disord. 2014 Apr;29(4):454-62. doi: 10.1002/mds.25844. Epub 2014 Mar 11. Review.

40.

Do prions cause Parkinson disease?: the evidence accumulates.

Olanow CW.

Ann Neurol. 2014 Mar;75(3):331-3. doi: 10.1002/ana.24098. Epub 2014 Feb 24. No abstract available.

PMID:
24615832
41.

Initiating levodopa therapy for Parkinson's disease.

Olanow CW, Kieburtz K, Stocchi F.

Mov Disord. 2014 Mar;29(3):430. doi: 10.1002/mds.25805. Epub 2014 Jan 9. No abstract available.

PMID:
24408661
42.

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A; LCIG Horizon Study Group.

Lancet Neurol. 2014 Feb;13(2):141-9. doi: 10.1016/S1474-4422(13)70293-X. Epub 2013 Dec 20. Erratum in: Lancet Neurol. 2014 Mar;13(3):240.

43.

Therapeutic prospects for Parkinson disease.

Olanow CW, Schapira AH.

Ann Neurol. 2013 Sep;74(3):337-47. doi: 10.1002/ana.24011. Review.

PMID:
24038341
44.

Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.

Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT.

Brain. 2013 Aug;136(Pt 8):2419-31. doi: 10.1093/brain/awt192.

45.

Levodopa-induced dyskinesias in the absence of nigrostriatal degeneration.

Bézard E, Olanow CW, Obeso JA.

Mov Disord. 2013 Jul;28(8):1023-4. doi: 10.1002/mds.25533. Epub 2013 Jun 20. No abstract available.

PMID:
23787890
46.

Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities.

Berg D, Lang AE, Postuma RB, Maetzler W, Deuschl G, Gasser T, Siderowf A, Schapira AH, Oertel W, Obeso JA, Olanow CW, Poewe W, Stern M.

Lancet Neurol. 2013 May;12(5):514-24. doi: 10.1016/S1474-4422(13)70047-4. Epub 2013 Apr 11.

PMID:
23582175
47.

Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients.

Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, Turner DA, Stacy M, Lang AE, Lozano AM, Olanow CW.

Neurology. 2013 Apr 30;80(18):1698-701. doi: 10.1212/WNL.0b013e3182904faa. Epub 2013 Apr 10.

48.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
49.

Obstacles to the development of a neuroprotective therapy for Parkinson's disease.

Stocchi F, Olanow CW.

Mov Disord. 2013 Jan;28(1):3-7. doi: 10.1002/mds.25337. Review.

PMID:
23390094
50.

The vatican meeting on neuroprotection for Parkinson's disease.

Olanow CW, Obeso JA, Stocchi F.

Mov Disord. 2013 Jan;28(1):1-2. doi: 10.1002/mds.25356. No abstract available.

PMID:
23390093

Supplemental Content

Loading ...
Support Center